New Hepatitis C Drug's Cost, Though Lower Than Some Expected, Fuels Rx-Pricing Debate

Gilead Science's revelation Friday (Oct. 10) that it will charge $94,500 for a 12-week course of its newly approved hepatitis C drug Harvoni, though less than some market analysts had expected, stoked the national drug pricing debate. The Campaign for Sustainable Rx Pricing criticized Harvoni's price and urged Congress to make drug companies justify the price of expensive pharmaceuticals. Medicaid health plans simultaneously released a report detailing prescribing and coverage restrictions states have employed to manage the high cost of...